GlassScriptPhysician profile
Susan Mandel
NPI 1457385312
$1,330.93
in general payments reported to CMS, 2019-2025
15 companies · $364 in 2025
The $364 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $15.18 · 2022: $522 · 2023: $26.66 · 2024: $179 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $507.70 | 2022 | |
| Amgen INC. | $221.32 | 2024-2025 | Evenity, Prolia |
| Nevro Corp. | $123.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.17 | 2019-2025 | Ofev |
| Pfizer INC. | $59.42 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $52.44 | 2024-2025 | Acthar |
| Lilly USA, LLC | $47.57 | 2019-2025 | Taltz, Zepbound |
| Ucb, INC. | $32.06 | 2025 | Bimzelx |
| Mallinckrodt Enterprises LLC | $32.03 | 2019 | |
| Genentech USA, INC. | $28.52 | 2025 | Actemra |
| Glaxosmithkline, LLC. | $28.09 | 2025 | Benlysta |
| Mindera Corp | $27.72 | 2025 | |
| Abbvie INC. | $23.41 | 2025 | |
| Novo Nordisk INC | $17.10 | 2019 | |
| Merck Sharp & Dohme LLC | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.